Invention Grant
- Patent Title: Quinoxaline derivatives as tyrosine kinase activity inhibitors
- Patent Title (中): 喹喔啉衍生物作为酪氨酸激酶活性抑制剂
-
Application No.: US12663698Application Date: 2008-06-06
-
Publication No.: US08193189B2Publication Date: 2012-06-05
- Inventor: Marc Gerspacher , Pascal Furet , Eric Vangrevelinghe , Carole Pissot Sondermann , Christoph Gaul , Philipp Holzer
- Applicant: Marc Gerspacher , Pascal Furet , Eric Vangrevelinghe , Carole Pissot Sondermann , Christoph Gaul , Philipp Holzer
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Laura K. Madden
- Priority: EP07109880 20070608; EP07150266 20071220
- International Application: PCT/EP2008/057058 WO 20080606
- International Announcement: WO2008/148867 WO 20081211
- Main IPC: A61K31/495
- IPC: A61K31/495
Abstract:
The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R6 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.
Public/Granted literature
- US20100168062A1 Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors Public/Granted day:2010-07-01
Information query
